Cogent Biosciences Inc
General ticker "COGT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $977.4M
Cogent Biosciences Inc follows the US Stock Market performance with the rate: 52.7%.
Estimated limits based on current volatility of 2.7%: low 7.50$, high 7.95$
Factors to consider:
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.28$, 8.72$]
- 2024-12-30 to 2025-12-30 estimated range: [3.31$, 8.34$]
Financial Metrics affecting the COGT estimates:
- Negative: Non-GAAP EPS, $ of -2.40 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -23.21 <= 2.35
- Negative: Inventory ratio change, % of 100 > 1.08
- Positive: -3.48 < Investing cash flow per share, $ of -1.23
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term COGT quotes
Long-term COGT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $75.55MM | $147.84MM | $208.13MM |
| Operating Income | $-75.55MM | $-147.84MM | $-208.13MM |
| Non-Operating Income | $2.59MM | $4.88MM | $15.72MM |
| Interest Expense | $0.00MM | $3.99MM | $0.00MM |
| R&D Expense | $55.91MM | $121.63MM | $173.75MM |
| Income(Loss) | $-72.96MM | $-142.96MM | $-192.41MM |
| Profit(Loss) | $-72.96MM | $-142.96MM | $-192.41MM |
| Stockholders Equity | $214.18MM | $255.74MM | $257.80MM |
| Assets | $232.09MM | $300.81MM | $313.44MM |
| Operating Cash Flow | $-58.76MM | $-118.64MM | $-153.62MM |
| Capital expenditure | $1.72MM | $6.86MM | $2.80MM |
| Investing Cash Flow | $-1.72MM | $-124.72MM | $-97.82MM |
| Financing Cash Flow | $37.98MM | $163.56MM | $163.54MM |
| Earnings Per Share* | $-1.85 | $-2.26 | $-2.42 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.